Product Reports Resources Pricing Login Book a demo
Stefano Buono
Person deep dive

Stefano Buono

Stefano Buono is an Italian physicist who founded Advanced Accelerator Applications in 2002 to commercialise a CERN patent, and Novartis bought it for $3.9B in 2018. In 2021 he co-founded newcleo, a nuclear reactor developer that listed on Nasdaq through a SPAC merger in September 2026.

Education
University of Turin

Track record

Companies Stefano Buono founded or backed, with what became of them.

newcleo

Firmnewcleo
Founded2021
FocusNuclear reactors and fuel

Career

  1. 1991Took a master's degree in physics at the University of Turin.
  2. 1990sWorked for about ten years with Nobel laureate Carlo Rubbia at CERN, helping develop its Adiabatic Resonance Crossing method.
  3. 1990sLed a team at CRS4 in Sardinia for six years on energy production and nuclear-waste transmutation.
  4. 2002Founded Advanced Accelerator Applications to commercialise a CERN patent in radiopharmaceuticals.
  5. 2015Advanced Accelerator Applications listed on the Nasdaq Global Select Market on 11 November.
  6. 2017Novartis agreed in October to buy Advanced Accelerator Applications for $3.9B, a 47% premium.
  7. 2018The Novartis deal closed on 22 January, weeks after US approval of its cancer drug Lutathera; he left as CEO and founded Elysia Capital.
  8. 2021Co-founded newcleo; it raised €400M in its first year.
  9. 2026newcleo closed an $85M round in February, taking its total raised since 2021 above $755M.
  10. 2026newcleo began trading on Nasdaq under the ticker NWCL on 22 September, raising about $247M in the merger.

Sources: Wikipedia: Stefano Buono · Wikipedia: Advanced Accelerator Applications · Dealroom: newcleo lists on Nasdaq with $250M SPAC deal · NucNet: newcleo closes $85M funding round · IAEA: Stefano Buono biography.

Companies founded

Currently

Active roles, board seats and partnerships.

Orderofmalta
Counsellor of the Grand Chancellor · 2025 – present
LIFTT
Chairman of the Board · 2019 – present
→
Planet Smart City
Chairman of the Board · 2018 – present
$220M valuation (2025)
→
Trained Therapeutics Discovery
Chairman of the Board

Work history

Past roles by Dealroom records.

Gauss Fusion
Board Advisor · 2023 – 2026
→
Abeona Therapeutics
Board Member · Director · 2018 – 2020
$141.2M valuation (2026)
CRS4
Manager · 1996 – 2002
CERN
Senior researcher · 1991 – 2002

Education

University of Turin
Msc · Physics · 1985 – 1991
← All people